Abstract
Shiga toxin (Stx)–producing Escherichia coli is the offending agent of postdiarrhea-associated hemolytic uremic syndrome (HUS), a disorder of glomerular ischemic damage and widespread microvascular thrombosis. We previously documented that Stx induces glomerular complement activation, generating C3a responsible for microvascular thrombosis in experimental HUS. Here, we show that the presence of C3 deposits on podocytes is associated with podocyte damage and loss in HUS mice generated by the coinjection of Stx2 and LPS. Because podocyte adhesion to the glomerular basement membrane is mediated by integrins, the relevance of integrin-linked kinase (ILK) signals in podocyte dysfunction was evaluated. Podocyte expression of ILK increased after the injection of Stx2/LPS and preceded the upregulation of Snail and downregulation of nephrin and α-actinin-4. Factor B deficiency or pretreatment with an inhibitory antibody to factor B protected mice against Stx2/LPS-induced podocyte dysregulation. Similarly, pretreatment with a C3a receptor antagonist limited podocyte loss and changes in ILK, Snail, and α-actinin-4 expression. In cultured podocytes, treatment with C3a reduced α-actinin-4 expression and promoted ILK-dependent nuclear expression of Snail and cell motility. These results suggest that Stx-induced activation of the alternative pathway of complement and generation of C3a promotes ILK signaling, leading to podocyte dysfunction and loss in Stx-HUS.
Shiga toxin (Stx)–producing Escherichia coli (STEC) is a causative agent of worldwide spread of diarrhea-associated hemolytic uremic syndrome (D+HUS), a disorder of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure that develops principally in infants and young children.1,2 Death or permanent ESRD occurs in about 12% of patients 4 years after D+HUS, and 20%–40% of survivors demonstrate long-term renal sequelae.3
After ingestion of contaminated food or water by STEC, Stx1 and Stx2 are transported into the circulation, where they bind to the globotriaosyl ceramide receptor expressed on the surface of target cells, including the glomerular endothelium, thereby activating a cascade of signals contributing to microvascular dysfunction, leukocyte adhesion, and thrombosis.4 We documented that Stx upregulated glomerular endothelial P-selectin expression and activated complement via the alternative pathway (AP), generating exuberant glomerular C3b deposits and C3a, which was instrumental to microvascular thrombus formation.5 A role for complement activation in D+HUS was first suggested by anecdotal studies showing reduced C3 and augmented C3b, C3c, and C3d serum levels in patients with active disease.6–8 More recently, high plasma levels of Bb and C5b-9 were measured in children with D+HUS, indicating complement AP activation during the onset of the disease.9 C3 deposition was detected on platelet–leukocyte complexes from patients with the acute phase of Stx-associated HUS.10
Reports, albeit controversial, of response to eculizumab in children with Stx-HUS,11 as well in the unusual outbreak in Germany,12–16 reinforce the role of complement in mediating glomerular lesions in Stx-associated HUS. In close proximity to glomerular endothelial cells, podocytes could represent a relevant target of Stx-induced complement activation. Podocytes possess an efficient contractile apparatus composed of F-actin and associated proteins interacting with the glomerular basement membrane (GBM) via integrins.17 Integrins transduce both “inside-out” and “outside-in” signals to associated intracellular molecules, including integrin-linked kinase (ILK), which regulates podocyte cell matrix interaction, proliferation, and slit diaphragm protein expression and distribution.18 Aberrant regulation of ILK signals drives toward podocyte dysregulation, which represents a crucial event in the development of proteinuria and renal function impairment in many forms of inherited or acquired glomerular diseases.19,20 In patients with D+HUS, retraction and collapse of the capillary tuft typically occurred in association with fusion of foot processes and swelling of podocytes.7,21–23 Podocyturia was documented in 15 children with D+HUS on the basis of nephrin and synaptopodin mRNA excretion, which reflected podocyte damage and detachment from the GBM.24 Moreover, in a baboon model of HUS, swelling of podocytes was found in association with glomerular endothelial lesions.25 A direct cytotoxic effect of Stx was evidenced by the release of inflammatory and vasoactive mediators by cultured podocytes.26,27
Here we sought to investigate whether glomerular activation of the AP of complement was responsible for podocyte damage in response to Stx in experimental HUS. We also wanted to evaluate the intracellular pathways involved in the regulation of slit diaphragm–associated proteins upon exuberant C3 deposition and C3a generation at the outer aspect of the GBM and mechanisms of damage.
Results
In Vivo Studies
Glomerular Complement Activation and Deposition, via the Alternative Pathway, Cause Podocyte Injury and Loss in Stx2/LPS Mice
C57BL/6 mice injected with Stx2 plus LPS developed thrombocytopenia, renal failure, and abundant C3 and fibrin(ogen) deposition, and platelet clumps in the glomerular capillary loops.5 Here, we confirmed that excessive glomerular C3 deposits, with an irregular distribution, are present at 24 and 48 hours after Stx2/LPS injection. C3 also accumulated on podocytes, as indicated by costaining with nephrin (Figure 1A, top). In the kidney of control mice, C3 staining was confined to a linear reactivity along the Bowman's capsule. In mice deficient for factor B (Bf−/−), a zymogen that carries the catalytic site of the AP C3 and C5 convertases,28 no glomerular C3 deposits were found after Stx2/LPS injection (Figure 1A, bottom).
Glomerular complement activation via AP causes podocyte loss/dysfunction in mice treated with Stx2/LPS. (A) Representative images of C3 deposits (green) in glomeruli of WT (top) and factor B–deficient (Bf−/−) mice (bottom) injected with saline (control) or Stx2/LPS at 24 and 48 hours. C3 deposits (green) accumulated on podocytes, as indicated by costaining with nephrin (red; yellow when merged). Original magnification, ×630. (B) Podocyte (WT1-positive cells) number per glomerulus and podocyte density and (C) nestin expression were evaluated in WT and Bf−/− mice injected with saline (control) or Stx2/LPS. Data are expressed as mean ± SEM (n=5 mice/group). *P<0.05; **P<0.01 versus WT control; #P<0.05; ##P<0.01 versus WT+Stx2/LPS at 48 hours. (D) Representative images of VEGF staining in glomeruli of WT and Bf−/− mice at 48 hours after saline (control) or Stx2/LPS injection (n=3 mice/group). Original magnification ×630.
To establish whether complement AP activation and deposition at the glomerular level could cause podocyte dysfunction and loss in experimental HUS, we evaluated podocyte number and density in renal tissue of Stx2/LPS-treated wild-type (WT) and Bf−/− mice by staining of the podocyte marker Wilms' tumor 1 (WT1). Both podocyte number per glomerulus and the density were significantly reduced in WT mice 24 hours after Stx2/LPS injection with respect to control mice; this reduction further worsened at 48 hours (Figure 1B). By contrast, podocyte loss was limited in Bf−/− mice after Stx2/LPS, so that the number and density of cells did not differ from values found in control Bf−/− mice (Figure 1B). Quantification of WT1-positive podocytes was validated by evaluating the expression of nestin, another podocyte marker.29,30 Nestin staining gradually decreased over time in WT mice injected with Stx2/LPS with respect to control mice, whereas Stx2/LPS mice deficient for factor B had preserved nestin expression (Figure 1C).
Ultrastructural analysis showed that WT mice after Stx2/LPS injection developed podocyte damage consisting of focal effacement of foot processes, as compared with podocyte morphology of control mice (Figure 2, A–C). This change was associated with endothelial cell swelling in several but not all glomerular capillary profiles. In Bf−/− mice, no ultrastructural changes were observed after Stx2/LPS (Figure 2D).
Glomerular complement activation via AP causes ultrastructural podocyte damage in Stx2/LPS mice. (A) Electron micrographs show intact foot processes of podocytes in control mouse kidney. (B) In glomerular capillaries of WT mice injected with Stx2/LPS focal areas of podocyte damage with effacement of foot processes are seen (arrowheads). (C) Podocyte damage (arrowheads) is also associated with endothelial cell swelling (asterisks). (D) Bf−/− mice do not show podocyte changes after Stx2/LPS.
To substantiate that glomerular complement activation in response to Stx2/LPS led to podocyte dysfunction, we evaluated in kidney sections of WT and Bf−/− mice the expression of vascular endothelial growth factor (VEGF), a podocyte-derived survival factor.31 Glomerular VEGF expression was reduced in WT mice at 48 hours after Stx2/LPS injection with respect to control mice (score, 1.57±0.15 versus 2.02±0.04; P<0.05) (Figure 1D). At variance, no changes in VEGF expression were found in Bf−/− mice injected with Stx2/LPS (score, 2.01±0.06 versus 2.0±0.07 in controls) (Figure 1D).
Glomerular Complement Activation Alters Podocyte Expression of ILK-Dependent Signals
We studied whether complement-dependent podocyte loss could be due to dysregulation of intracellular signals consequent to activation of ILK.32 In glomeruli of control mice a faint staining for ILK was observed. The expression of ILK markedly increased in glomeruli of WT mice 24 hours after Stx2/LPS injection and persisted thereafter (Figure 3A). Glomerular ILK expression was confined to podocytes, as indicated by colocalization with nephrin (Figure 3B, inset). That complement activation was instrumental to the ILK upregulation is documented by the weak staining for ILK detected at the glomerular level in Bf−/− mice injected with Stx2/LPS (Figure 3A).
Glomerular complement activation induces upregulation of ILK in glomeruli of HUS mice. (A) Representative images of double staining for ILK (red) and lectin (green) in WT and Bf−/− mice injected with saline (control) or Stx2/LPS at 24 and 48 hours (n=5 mice/group). (B) ILK expression (red) in podocytes stained in adjacent sections for nephrin (green). Renal sections are counterstained with lectin and DAPI (nuclei, blue). Original magnification, ×630.
Next, we investigated the expression of Snail, a transcriptional factor induced by ILK,33 known to regulate nephrin and other relevant genes involved in podocyte dysfunction.32 In WT mice with HUS, we found an intense glomerular staining for Snail at 24 hours that increased at 48 hours in podocytes, as confirmed by colocalization with nephrin (Figure 4, A and B). No staining was observed in control mice. Factor B deficiency, by limiting ILK activation, also prevented Stx2/LPS-induced increase of Snail expression (Figure 4A). In normal glomeruli, nephrin staining revealed a linear and thick pattern along the GBM (Figure 5A). Nephrin expression in response to Stx2/LPS decreased over time in WT, but not Bf−/−, mice (Figure 5, A and B).
Increased podocyte expression of Snail in response to Stx2/LPS is prevented in Bf−/− mice. (A) Representative images of Snail (red) in WT and Bf−/− mice injected with saline (control) or Stx2/LPS at 24 and 48 hours (n=5 mice/group). (B) Colocalization of Snail and nephrin (green) staining is shown by yellow staining. Nuclei are stained with DAPI (blue). Original magnification, ×630.
Nephrin expression is preserved in Bf−/−mice injected with Stx2/LPS. (A) Representative images of nephrin expression (green) in glomeruli of WT and Bf−/− mice injected with saline (control) or Stx2/LPS at 24 and 48 hours (n=5 mice/group). Renal sections were counterstained with lectin (red) and DAPI (nuclei, blue). Original magnification, ×630. (B) Quantification of nephrin expressed as percentage of positive area. Data are expressed as mean±SEM. **P<0.01 versus WT control; ##P<0.01 versus WT+Stx2/LPS at corresponding time.
α-Actinin-4 is an important F-actin–associated protein involved in the maintenance of podocyte architecture that, by interacting with integrins, stabilizes podocytes and regulates cell migration and detachment.33–35 In WT control mice, α-actinin-4 was strongly expressed by podocytes with a staining pattern similar to that of nephrin (Figure 6A), whereas it was reduced in Stx2/LPS mice at 24 hours and even more at 48 hours (Figure 6B). No difference in α-actinin-4 expression and distribution was found in Bf−/− mice treated with Stx2/LPS (Figure 6, A and B).
Loss of α-actinin-4 in glomeruli of Stx2/LPS mice is prevented by blockade of the alternative pathway of complement. (A) Representative images and (B) quantification of α-actinin-4 glomerular expression (red) in WT and Bf−/− injected with saline (control) or Stx2/LPS at 24 and 48 hours. Original magnification, ×630. Data are expressed as mean±SEM (n=5 mice/group). **P<0.01 versus WT control; ##P<0.01 versus WT+Stx2/LPS at 48 hours.
Effect of Treatment with Anti–Factor B Antibody in Stx2/LPS Mice
To validate the role of complement via AP on podocyte injury studied in the genetic model of Bf−/− mice, we evaluated the pharmacologic effect of the anti–factor B mAb 137936,37 on podocyte loss, ILK, and nephrin expression in Stx2/LPS mice. We found that treatment with the anti–factor B antibody protected Stx2/LPS mice from podocyte loss and restored ILK and nephrin expression (Supplemental Figure 1).
Treatment with C3a Receptor Antagonist Limits Podocyte Injury in Stx2/LPS Mice
Finding that mice with Stx-associated HUS showed abnormal glomerular complement activation could imply local generation of C3a and its contribution in triggering dysfunction and detachment of podocytes known to express C3a receptor (R).38,39 Treatment with the C3aR antagonist SB290157 reduced podocyte ultrastructural damage (Supplemental Figure 2) and limited podocyte loss in Stx2/LPS mice with respect to mice receiving vehicle, as determined by both staining with WT1 (Figure 7A) and nestin (Supplemental Figure 3A). Blocking of C3aR prevented ILK (Figure 7B, Supplemental Figure 3B) and Snail (Figure 7B) induction in podocytes of HUS mice. Moreover, SB290157 limited nephrin mRNA downregulation (Supplemental Figure 3C) and preserved α-actinin-4 expression, as indicated by immunofluorescence staining (Figure 7B, Supplemental Figure 3D, right) and Western blot analysis of renal tissue (Supplemental Figure 3D, left). Altogether, these data suggest a direct role of C3a in podocyte dysregulation in response to Stx2/LPS.
C3a generated by complement activation contributes to podocyte injury in HUS mice. (A) Podocyte number assessed at 24 and 48 hours in Stx2/LPS mice treated with vehicle or C3aR antagonist (SB290157). (B) Glomerular expression of ILK, Snail, and α-actinin-4 evaluated at 24 hours in Stx2/LPS mice treated with vehicle or C3aR antagonist. (C) Platelet count and serum BUN levels measured at 24 hours in Stx2/LPS mice treated with vehicle or SB290157. Mice injected with saline were used as control. Data are expressed as mean±SEM (n=5–6 mice/group at 24 hours, n=4 mice/group at 48 hours). **P<0.01 versus control; #P<0.05; ##P<0.01 versus vehicle.
Functional in vivo analyses showed that C3aR antagonist limited the decrease of platelet count in response to Stx2/LPS (Figure 7C). Renal function, which was severely impaired in Stx2/LPS mice, was partially ameliorated by SB290157 treatment, as indicated by serum BUN levels that were numerically, albeit not significantly, lower than those in mice given vehicle (Figure 7C). Urinary albumin-to-creatinine ratios increased 24 hours after Stx2/LPS injection (106.7±21.9 μg/mg for Stx2/LPS versus 54.3±3.1 μg/mg for controls; P<0.01) and were reduced by SB290157 (47.8±2.9 μg/mg; P<0.01 versus vehicle).
In Vitro Studies: C3a Induces Snail Activation via ILK Signaling Pathway
The role of C3a on podocyte dysregulation was explored in vitro by evaluating the expression of ILK and its downstream effector Snail in differentiated human cultured podocytes exposed to exogenous C3a. Podocytes constitutively exhibited a weak cytoplasmatic ILK localization at the focal adhesion sites, while in C3a-treated cells ILK protein greatly increased and was redistributed at the cell periphery at 6 and 15 hours (Figure 8A). In untreated podocytes, Snail staining mainly localized in the cell cytoplasm. Exposure to C3a induced Snail protein expression at the nuclear level (Figure 8B, top). The percentage of cells with nuclei positive for Snail significantly increased (P<0.001) upon C3a incubation at 6 and mostly at 15 hours compared with control cells (C3a was 40.0%±2.0% at 6 hours and 46.0%±2.0% at 15 hours versus 7.2%±1.0% for control cells). When podocytes were silenced for ILK expression with small interfering mRNA (siILK), as shown by real time RT-PCR analysis (Figure 8B, middle), Snail protein expression in response to C3a was markedly reduced at 15 hours (Figure 8B, middle). Score analysis of Snail nuclear staining showed that in C3a-treated podocytes transfected with control nontarget small interfering RNA (siNull), most nuclei ranged between scores of 2 and 3 (40.1%±5.6% and 38.3%±4.3% Snail-positive nuclei, respectively) compared with control cells, which showed very weak positivity (Figure 8B, bottom). In ILK-silenced cells treated with C3a, Snail expression was limited, as shown by a significantly higher percentage of Snail-positive nuclei with scores between 0 and 1 (32.2%±2.7% and 44.8%±2.8%, respectively).
C3a induces ILK-dependent Snail activation in human cultured podocytes. (A) Effect of C3a (1 μM) on ILK (red) expression in human differentiated podocytes at 6 and 15 hours. Nuclei are stained with DAPI (blue). Original magnification, ×400. (B) (Top) Effect of C3a on Snail (red) protein expression in podocytes at 6 and 15 hours. (Middle) ILK mRNA expression in control podocytes or cells transfected with siNull or siILK. Data are expressed as mean±SEM (n=3 experiments). *P<0.001 versus control and siNull. Representative images showing Snail (red) expression in human podocytes transfected with siNull or siILK and exposed for 15 hours to C3a. Nuclei are stained with DAPI (blue). Original magnification, ×400. (Bottom) Semiquantitative score analysis of Snail-positive nuclei in podocytes exposed to medium (control) or transfected with siNull or siILK and then treated with C3a for 15 hours. Data are expressed as mean percentage±SEM in 15 random fields per sample (n=6 experiments). *P<0.001 versus control; #P<0.01; ##P<0.001 versus C3a+siNull.
A direct role for C3a on the regulation of α-actinin-4 expression rests on Western blot analysis data showing that exogenous C3a decreased α-actinin-4 protein expression after 6 hours compared with unstimulated cells (Figure 9A). Downregulation of α-actinin-4 persisted until 15 hours (densitometric analysis: C3a was 0.79±0.2 at 15 hours versus 1 in control cells; P<0.001).
C3a decreases α-actinin-4 expression and promotes ILK-dependent podocyte migration. (A) Representative Western blotting of α-actinin-4 expression in extracts of podocytes exposed to medium (control) or C3a (1 μM) for 6 hours. Densitometric analysis is expressed as mean±SEM (n=6 experiments). *P<0.001 versus control. (B) Podocyte migration evaluated by wound healing assay in cells exposed to medium alone (control), C3a, or transfected with siNull or siILK before exposure to C3a for 24 hours. Data are expressed as mean ± SEM (n=6 experiments). *P<0.01 versus control; #P<0.01 versus siILK+C3a.
Finally, we assessed whether C3a was able to modulate podocyte motility by wound healing assay. As shown in Figure 9B, exposure to C3a significantly increased podocyte migration over time compared with control cells. Moreover, ILK knocking down by siILK prevented podocyte migration in response to C3a with respect to cells transfected with siNull (Figure 9B), thereby highlighting the functional link between ILK and C3a-induced podocyte motility.
Discussion
Long-term renal prognosis of D+HUS remains a controversial issue. More than 70% of patients with STEC-HUS fully recover from the acute disease, although long-term renal sequelae have been reported in up to 20%–40% of patients who experience a critical reduction in nephron number with unsustainable remnant single-nephron hyperfiltration, proteinuria, glomerular injury, and CKD.3,40 The need for identifying determinants of glomerular damage to understand and predict the reasons for long-term renal prognosis is still a critical priority for designing targeted treatments of high-risk patients. Because kidney biopsies are rarely performed in the acute phase of the disease, few data are available to show glomerular endothelial alterations, fibrinogen, and C3 deposits in association with podocyte foot process fusion in patients with D+HUS.23 Podocyte loss was documented in patients with active D+HUS by the presence of podocyturia based on urinary excretion of mRNA for nephrin and synaptopodin, which were suggested as possible biomarkers of glomerular injury and long-term renal outcome.24
Here we take advantage of a mouse model of HUS that allowed us to previously document that Stx promotes glomerular inflammation41 and complement activation, via P-selectin, as a key mechanism of C3a-dependent loss of endothelial thromboresistance and microvascular thrombosis.5 The present study demonstrates that in Stx2/LPS-treated mice, activation and deposition of the glomerular complement proteins are functionally linked to podocyte ultrastructural damage, associated with endothelial swelling in several but not all glomerular capillaries and with a remarkable reduction of podocyte number and density, which are prevented by blockade of the complement AP activation, as observed in factor B–deficient mice.
In search for mechanisms underlying complement-dependent podocyte dysfunction and detachment, we focused on ILK, an essential component of the integrin signaling pathway. ILK is activated in the damaged podocyte and is associated with alterations in cell phenotype, cell–cell and cell–matrix interaction, and motility.32,42 Ectopic expression of exogenous ILK in cultured podocytes by adenoviral vectors, harboring FLAG-tagged ILK gene, results in suppression of nephrin and ZO-1 and de novo expression of desmin and α-smooth muscle actin, indicating cytoskeletal protein alterations with consequent disruption of slit diaphragm integrity and increased cell motility.32 On the other hand, activated ILK, possibly via phosphorylation/inactivation of its downstream target glycogen synthase kinase-3β,43 leads to increased expression of Snail,32 a direct suppressor of nephrin in podocytes.44 Dysregulation of ILK activity has been implicated in the pathogenesis of several CKDs, including diabetic nephropathy, congenital nephrotic syndrome, and experimental models of glomerular nephropathy.42,45,46 Here, we provide data showing in Stx2/LPS-treated mice a marked induction of ILK and Snail protein at the podocyte level, as documented by nephrin costaining. The finding that the expression of ILK and Snail are remarkably lower in glomeruli of factor B–deficient mice with respect to WT mice with HUS indicates a functional link between glomerular C3 activation and ILK-induced Snail pathway. Next, we have examined whether complement-dependent ILK overexpression could influence podocyte architecture and consequent glomerular filtration barrier by affecting one of the most relevant slit-diaphragm proteins, nephrin, a known target of Snail. In WT mice with HUS, podocytes exhibit a significant reduction of the characteristic pattern of nephrin staining, which is instead preserved by factor B deficiency. Another striking feature in glomeruli of Stx2/LPS mice is the aberrant distribution of α-actinin-4, an actin cross-linking protein regulating focal adhesion, intracellular tension, and cell adhesion.34,47 In this respect, data show that in α-actinin-4–deficient mice the presence of WT1-positive podocytes in the urine closely correlated with a decrease in podocyte number.34 In our experimental setting, similarly to nephrin, the pattern of α-actinin-4 protein is almost normalized in factor B–deficient mice. Besides the genetic model of factor B–deficient mice, the role of complement activation via AP pathway has also been evaluated by pharmacologic inhibition of factor B with a functional blocking antibody,36,37 showing protection from podocyte loss and restoration of ILK and nephrin expression in Stx2/LPS mice.
Our data also corroborate the novel concept that intraglomerular C3a, possibly generated during complement activation and deposition in response to Stx, is a key factor of podocyte damage. Actually, treatment with a C3aR antagonist reduces podocyte ultrastructural changes and loss by limiting ILK and Snail activation and restoring α-actinin-4. Thrombocytopenia and renal function also improved. These findings would indicate C3a as a potential new target for clinical therapeutic strategies in D+HUS.
The possible intracellular pathways underlying C3a-dependent podocyte dysfunction are highlighted in Figure 10. The mechanisms identified in the in vivo model have been further validated by experiments in cultured podocytes showing a direct role for C3a as mediator of ILK-dependent Snail activation. Cells exposed to C3a exhibit a marked redistribution/increase of ILK staining, associated with enhanced nuclear Snail and reduced α-actinin-4 protein expression that are both normalized by ILK silencing. Our data are consistent with a study showing that podocyte-specific ablation of ILK caused aberrant distribution of nephrin and α-actinin-4, which indicates that ILK is essential in specifying the distribution of slit diaphragm–associated proteins and in preserving podocyte architecture.18 Of interest, podocyte lines generated from α-actinin-4–deficient mice were less adherent than WT cells to the GBM matrix components.34 We finally demonstrate that C3a added exogenously to podocytes markedly increases cell motility in a time-dependent manner. It is key mechanistically that when ILK—and consequently ILK-dependent Snail activation—is inhibited by small interfering RNA, we observe normalization of C3a-dependent podocyte motility, pointing to ILK as a relevant mediator of complement-dependent podocyte dysregulation. The enhanced cell motility induced by C3a possibly reflects, in vivo, a condition of podocyte phenotypic alteration translating into abnormal cell–cell interaction and cell–matrix adhesion to GBM that can lead to cell detachment and disruption of the glomerular filtration barrier.34
C3a generated by glomerular complement activation via AP in response to Stx causes podocyte dysfunction. The scheme summarizes the possible sequence of events through which C3a, by binding C3aR on podocyte surface can stimulate, via phosphatidylinositol 3-kinase (PI3K), ILK activity that, in turn, can inhibit glycogen synthase kinase (GSK)-3β. The inhibition of the GSK-3β leads to increased Snail expression and nuclear localization and the consequent downregulation of nephrin expression.
In conclusion, our study strengthens the notion that Stx-dependent glomerular complement deposition and C3a generation play a determinant role in the development of podocyte structural abnormalities and loss, intrinsically coupled to ILK-dependent signaling. Should the present finding of complement AP activation be documented in human Stx-associated HUS, drugs such as eculizumab, already used for atypical HUS with astonishing results,48,49 will represent a valuable treatment option, at least for patients who have Stx-HUS and neurologic signs or who need dialysis.
Concise Methods
Experimental Model of HUS
Male C57BL/6 mice were obtained from Charles River Laboratories Italia (Lecco, Italy). Factor B–deficient (Bf−/−) mice of C57BL/6 genetic background50 and WT mice were a kind gift of Dr. Marina Botto (Imperial College, London, UK). For the study, Bf−/− mice and control WT littermates were obtained by heterozygote×heterozygote matings at Mario Negri Institute. Genotypes were determined by PCR.50 Animal care and treatment were in accordance with institutional guidelines in compliance with national and international laws and policies.5 Animal studies were approved by the institutional animal care and use committees of Mario Negri Institute, Milan, Italy. HUS was induced in mice (26–28 g body weight) by intraperitoneal injection of Stx2 (100 ng per mouse; Toxin Technology, Sarasota, FL) plus LPS (50 μg per mouse; O111:B4; Sigma-Aldrich, St. Louis, MO). Mice injected with saline served as controls. Stx2 was chosen because it is associated with HUS clinical isolates more often than Stx151 and because of the evidence that Stx2 injected in mice is more toxic and accumulates in the kidney to a greater extent that does Stx1.52 Mice were euthanized at 24 or 48 hours after injection. Selected experiments included treatment of HUS mice with the C3aR antagonist SB290157 (Calbiochem, EMD Millipore Corp., Billerica, MA) at a dose of 15 mg/kg intraperitoneally five times a day (i.e., 1 hour before and 1, 4, 8, and 23 hours after Stx2/LPS injection) or an equal volume of vehicle. For mice followed until 48 hours, four additional injections of SB290157 were performed (i.e., 26, 30, 34, and 47 hours after Stx2/LPS). Blood platelet count, renal function measured by serum BUN (Reflotron test; Roche Diagnostics, Basel, Switzerland), urinary albumin (ELISA; Albwell M Exocell, Philadelphia, PA), and urinary creatinine (Cobas Mira autoanalyzer; Roche Diagnostics) were assessed. Additional mice were treated with anti–factor B mAb 1379, an inhibitor of the alternative pathway of complement,36,37 at a dose of 3 mg per mouse intraperitoneally, or with PBS, 2 hours before Stx2/LPS injection; the mice were euthanized at 24 hours. A second dose of mAb 1379 was administered (at 24 hours) to mice euthanized at 48 hours after Stx2/LPS.
Immunofluorescence and Immunohistochemistry Analysis in Renal Tissue
C3 deposits were evaluated by incubating 3-μm periodate lysine paraformaldehyde–fixed renal samples with FITC-conjugated goat anti-mouse C3 antibody (1:200; Cappel, Durham, NC). Stainings for ILK and nephrin were performed in optimal cutting temperature–frozen serial sections incubated with rabbit anti-ILK antibody (1:200; Abcam, Cambridge, UK) or goat anti-nephrin antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA), followed by Cy3 or FITC-conjugated secondary antibody (1:100 or 1:400; Jackson ImmunoResearch Laboratories, West Grove, PA). Snail and α-actinin-4 were detected in periodate lysine paraformaldehyde–fixed frozen kidney samples by using rabbit anti-Snail antibody (1:400; Abcam) and rabbit anti–α-actinin-4 antibody (1:300; OriGene Technologies, Rockville, MD), followed by Cy3-conjugated secondary antibody (1:200; Jackson ImmunoResearch Laboratories). Nuclei and cell membranes were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and rhodamine or FITC–wheat germ agglutinin–lectin, respectively. Positive stainings of nephrin and α-actinin-4 were quantified in 15–20 glomeruli randomly selected in each section, by using ImageJ software (National Institutes of Health, Bethesda, MD) expressing the positive areas as a percentage of the total area. Negative controls were obtained by omitting the primary antibody on adjacent sections. Samples were examined under confocal inverted laser microscopy (LSM 510 Meta; Zeiss, Jena, Germany). An immunoperoxidase method53 was used for detection of VEGF using goat anti-VEGF antibody (1:10; R&D Systems, Minneapolis, MN). Intensity of glomerular VEGF signal was graded on a scale of 0–3 (0, no staining; 1, weak staining; 2, staining of moderate intensity; 3, strong staining). Negative controls were obtained by omitting the primary antibody on adjacent sections (data not shown).
Glomerular Podocyte Quantification
Podocytes were identified as cells positive for WT1. Optical cutting temperature–frozen kidney sections were incubated with rabbit anti-WT1 antibody (1:400; Santa Cruz Biotechnology), followed by Cy3-conjugated goat anti-rabbit IgG (1:100; Jackson ImmunoResearch Laboratories). Nuclei and cell membranes were counterstained with DAPI and FITC–wheat germ agglutinin–lectin. At least 30 glomeruli per section for each animal were randomly acquired by confocal laser scanning microscope. The estimation of the average number of podocytes per glomerulus and the glomerular volume were determined by morphometric analysis proposed by Weibel.54 The number of podocytes per glomerular volume was calculated using a computer-based image-analysis system (Mac OS 09; Apple Computer, Cupertino, CA) as previously described.55 In addition, podocyte area was quantified by evaluating nestin expression with a rat anti-mouse nestin (1:300; Abcam) followed by FITC goat anti-rat antibody (1:100; Jackson ImmunoResearch Laboratories).
Renal Ultrastructural Analysis
Fragments of kidney tissue were processed as described elsewhere.41 Ultrathin sections were stained with uranyl acetate and lead citrate and examined using a transmission electron microscope (Morgagni 268D; Philips, Brno, Czech Republic).
Cell Culture and Incubation
Conditionally immortalized human podocytes (kindly provided by Dr. Saleem Children’s Renal Unit and Academic Renal Unit, University of Bristol, UK) were grown as previously described.56 Briefly, cells were cultured under growth-permissive conditions at 33°C in RPMI 1640 medium (Invitrogen, Gaithersburg, MA) supplemented with 10% FBS (Invitrogen), insulin (10 μg/ml), transferrin (5.5 μg/ml), and sodium selenite (5 ng/ml) (Invitrogen) and 100 U/ml penicillin plus 0.1 mg/ml streptomycin (GIBCO-Invitrogen). To induce differentiation, podocytes were grown on rat collagen type I (BD Bioscience, Franklin Lakes, NJ) and maintained in nonpermissive conditions at 37°C for 12 days. Fifteen hours before and during the experiments, podocytes were maintained in serum free conditions. Podocytes were incubated with exogenous C3a (1 μM; Calbiochem) or medium alone for different time periods; protein expression of ILK, Snail, α-actinin-4, and cell migration were then studied.
Immunofluorescence Analysis In Vitro
Cells fixed in 2% paraformaldehyde (Electron Microscopy Science, Hatfield, PA) and 4% sucrose (Sigma-Aldrich, Milan, Italy) were incubated with 0.3% Triton X-100 (Sigma-Aldrich) and then with blocking solution consisting of 2% FBS (Invitrogen), 2% BSA (Sigma-Aldrich), and 0.2% bovine gelatin (Sigma-Aldrich). Cells were incubated with rabbit monoclonal anti-ILK antibody (1:250; Abcam) or with rabbit polyclonal anti-Snail antibody (1:200; Abcam) and then with goat anti-rabbit Cy3-conjugated as secondary antibody (1:80; Jackson ImmunoResearch Laboratories). Cells nuclei were stained with DAPI. Samples were examined under confocal inverted laser microscopy (LSM 510 Meta). Quantification of Snail-positive nuclei per total number of DAPI-positive nuclei was assessed in 15 random fields per sample.
Silencing of ILK Gene
Human podocytes were transfected by Nucleofection (Amaxa) with ON-Target plus SMART pool (Dharmacon; L-004499–00–0005) siILK or siNull (Silencer Select Negative Control #2 siRNA; Ambion) using the Amaxa Human NHDF Nucleofector Kit (VPE-1001; LONZA). Forty-eight hours after transfection, silencing of ILK was confirmed by real time RT-PCR. Podocytes transfected or not transfected with siNull or siILK were exposed to control medium or exogenous human C3a (1 μM; Calbiochem) for 24 hours and were analyzed for wound healing assay. For quantification of Snail staining, the nuclear signal in control cells, siNULL-transfected or siILK- transfected podocytes was graded on a scale of 0 to 3 (Snail expression: score 0=no nuclear staining; score 1=1%–30% nuclear staining; score 2=31%–60% nuclear staining; and score 3=61%–100% nuclear staining) in 15 random fields per sample.
Wound Healing Assay
Migration was assessed in confluent podocytes scratched with a 200-μl pipette tip to create a cell-free denuded area. Before scratching, cells were transfected or not transfected with siNull or siILK and then incubated with exogenous human C3a (1 μM) for 24 hours. Control cells exposed to medium alone were also tested. Podocytes were monitored by phase-contrast under a 10× objective on time-lapse microscopy (Axio Imager.z2 microscopy; Zeiss). Images were taken at different time intervals (2, 6, 10, 16, 20, and 24 hours), and the number of cells migrated into the wound track was counted at each time point (n=5 fields per well).
Quantitative Real-Time PCR
Total RNA was isolated from mouse renal tissue or human podocytes by TRIzol Reagent (Invitrogen). Contaminating genomic DNA was removed by RNase-free DNase (Promega, Ingelheim, Germany) for 1 hour at 37°C. Two micrograms of purified RNA was reverse transcribed using random hexamers (50 ng) and 50 U of SuperScript II RT (Invitrogen) for 1 hour at 42°C. No enzyme was added for reverse transcription–negative controls. Amplification was performed on 7300 Real Time PCR System with SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer’s protocol. The following primers were used: mouse nephrin (300 nM) forward 5′- TTTCTACCGCCTCAACGTGTT -3′, reverse 5′- GCACTTGCTCTCCCAGGAACT -3′; mouse GAPDH (300 nM) forward 5′- TCATCCCTGCATCCACTGGT -3′, reverse 5′- CTGGGATGACCTTGCCCA -3′; human ILK (300 nM) forward 5′- GCAGCCCGAGTCCCGAGGATA-3′, reverse 5′- GCGCCGAGTCCCCTGGATTG-3′; 18S (50 nM) forward 5′- ACGGCTACCACATCCAAGGA -3′, reverse 5′-CGGGAGTGGGGTAATTTGCG-3′. The ΔΔCt technique was used to calculate cDNA content in each sample using the cDNA expression in renal tissue from WT control mice or human control podocytes as calibrator.
Western Blot Analysis
Frozen kidney tissues were homogenized in lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 10% glycerol, 1% Triton X-100, Sigma-Aldrich protease inhibitor cocktail), whereas cultured podocytes were lysed in radioimmunoprecipitation assay buffer (0.1% sodium dodecyl sulfate, 0.5% deoxycholate, 1% Triton X-100, 20 mM HEPES [pH 7.5], 150 mmol/L NaCl, 1 mM EDTA, Sigma-Aldrich protease inhibitor cocktail). Protein concentration was determined by DC assay (Bio-Rad Laboratories, Hercules, CA). Equal amounts of proteins were separated on SDS-PAGE under reducing conditions and transferred to nitrocellulose or polyvinylidene difluoride membranes (Bio-Rad Laboratories). After blocking with 5% BSA in Tris-buffered saline supplemented with 0.1% Tween-20 (Sigma-Aldrich), membranes were incubated with a rabbit monoclonal anti–α-actinin-4 antibody (1:1000; OriGene Technologies). A rabbit anti-actin antibody (1:3000; Sigma-Aldrich) was used to control for loading differences. The signal was visualized using goat anti-rabbit horseradish peroxidase–conjugated secondary antibodies and ECL Western blotting Detection Reagent (Thermo Fisher Scientific, Rockford, IL). Bands were quantified by densitometry using ImageJ software.
Statistical Analyses
Results are expressed as mean±SEM. Data were analyzed by the nonparametric Mann–Whitney or Kruskal–Wallis test or by ANOVA coupled with Bonferroni post hoc analysis, as appropriate. P values <0.05 were considered to represent statistically significant differences.
Disclosures
None.
Acknowledgments
We thank Mauro Abbate and Marina Noris for helpful suggestions and criticism and Lorena Longaretti and Cristina Zanchi for real time RT-PCR experiments. We are indebted to Giovanna Barcella, Romana Stacchetti, Cinzia Calvi, and Luciana Prometti for animal care. Manuela Passera helped in preparing the manuscript. Paola Rizzo is a recipient of a fellowship from Fondazione Aiuti per la Ricerca sulle Malattie Rare (ARMR), Bergamo, Italy.
Footnotes
M.L. and S.B. contributed equally to this work.
Published online ahead of print. Publication date available at www.jasn.org.
This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2013050450/-/DCSupplemental.
- Copyright © 2014 by the American Society of Nephrology